Assessments REA (2016 – 2020)

Home  /  Assessments REA (2016 – 2020)
Project IDPatient InvolvementTitlePublication of Final Assessment1st AuthorsCo-AuthorsDedicated ReviewersPublication of Project Plan
Pharmaceutical technologies
PTJA04Sotagliflozin for Type 1 diabetes mellitus
Patient Input - Diabetes Type 1
TBDTLVZINAEMPS, SNHTA, NVD, INFARMED, NCPE, AOTMiT
Observer: HIS, EOF
TBD
PTJA03
Alecensa as monotherapy is indicated for the first-line treatment of adult patients with ALK+ advanced NSCLC23.01.2018TLVHVB, AAZNICE, Regione Veneto, AETSA, NIPN
Observer: MOH MALTA
20.10.2018
PTJA02Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib treatment25.10.2017HASINFARMEDAAZ, SNHTA, FIMEA, LBI-HTA, NIPN, AETSA
Observer: EOF, EKAPTY
10.07.2017
PTJA01
Midostaurin for the indication of Acute Myeloid Leukaemia08.11.2017FIMEANOMATLV, ZIN, HAS, NICE, AEMPS
Information retrieval: IQWIG
Observer: SUKL, SU, EOPPY, SESCS
20.06.2017
Other Technologies
OTCA18Regional hyperthermia for high-risk soft tissue sarcoma treatmentTBDNIPHNORERVASPVT, AETS-ISCIII, SNHTATBD
OTCA17Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)TBDAGENASRERSNHTA, AETSATBD
OTCA16Bioresorable Stents in cardiovascular indications (coronary artery disease)23.12.2018IAMEV/LBI-HTASNSMPSSESCS, HASTBD
OTCA15Irreversible electroporation in liver and pancreatic cancerTBDAVALIA-TLBI-HTAVASPVT, NIPN, SNHTATBD
OTCA14Robotic surgery in thoracic and visceral indications 3.12.2018LBI-HTAReg. VenetoHIQA, DEFACTUM11.07.2018
OTCA13Vagal nerve blockade for obesityCancelled: expiration of CE approval for the technologyNIPHNOVASPVTSESCS/FUNCANIS, NIPHBCancelled: expiration of CE approval for the technology
OTCA12The use of C-reactive protein point-of-care testing (CRP POCT) to guide antimicrobial prescribing in primary care settings for respiratory tract infections (RTIs)29.9.2018HIQAHVBUCSC Gemelli, AETSA, AGENAS, HIS
Observer: AOTMiT
19.4.2018
OTCA11The use of 3D printing for implants and splints in connection with surgeryTBDDEFACTUMOSTEBAGÖG, KCE, AAZ, NIPNTBD
OTJA10Stool DNA testing (e.g. ColoAlert, ColoGuard) for early detection of colorectal cancerTBDGÖGNIJZ, JAZMPNICE, AGENAS, DEFACTUM, OSTEBATBD
OTCA09High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer12.04.2018LBI-HTAVASPVTSNHTA, AETS-ISCIII, OSTEBA26.02.2018
OTJA08
Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin 20.07.2018AAZHVB, NIPHNOAQuAS, HIS, RER
Observer: ACSS-IP, AOTMiT
28.02.2018
OTCA07Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard ultrasound phacoemulsification cataract surgery22.10.2018 - 26.10.2018RERGOG, HASKCE, Osteba, SESCS/FUNCANIS and AQuAS
Observer: VASPVT
15.2.2018
OTCA06Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical riskPublication date forthwithAGENASNIPHNOSNHTA, OCSC, HIQA, KCE, REGIONE VENETO08.11.2017
OTCA05Repetitive transcranial magnetic stimulation for treatment-resistant major depression21.04.2017LBI-HTAOstebaKCE, FUNCANIS21.04.2017
OTCA04
Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer3.1.2018ZINKCELBI-HTA, HAS10.11.2017
OTCA03Screening of fetal aneuploidies whereby non-invasive prenatal test (NIPT)9.02.2018Avalia-tRERMIDT, SNHTA, NIPN, IQWIG
Observer: EOPYY
22.03.2017
OTCA02Antibacterial-coated sutures versus non-antibacterial-coated sutures for the prevention of abdominal, superficial and deep, surgical site infection (SSI)27.04.2017AAZNSPHMPDBSUKL, NIPN/OGYEI, VASPVT, SNHTA, IQWIG06.10.2016
OTCA01Wearable cardioverter-defibrillator (WCD) therapy
in primary and secondary prevention of sudden cardiac arrest in patients at risk
30.11.2016LBI-HTAAAZIQWIG, AVALIA-T18.08.2016

Bold means the assessment is ongoing. What does this icon  mean? Patients have been involved in this assessment.

General abbreviations: OT-other technologies, PT-pharmaceutical technologies, CA-collaborative assessment, JA-joint assessment

Assessment FAQs

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.